Tharimmune, Inc.
Status: Publicly traded
Direct answer
Tharimmune, Inc. is publicly traded on NASDAQ under the ticker THAR.
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid...
Can you invest in Tharimmune, Inc.?
Yes. Tharimmune, Inc. is publicly traded on NASDAQ under the ticker THAR.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Tharimmune, Inc.
Detailed equity research is provided by MarketSnap.